- Home
- BROG vs ATOS Comparison
BROG vs ATOS Comparison
Compare BROG & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BROG
- ATOS
- Stock Information
- Founded
- BROG 2019
- ATOS 2009
- Country
- BROG United Arab Emirates
- ATOS United States
- Employees
- BROG N/A
- ATOS N/A
- Industry
- BROG Integrated oil Companies
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- BROG Energy
- ATOS Health Care
- Exchange
- BROG Nasdaq
- ATOS Nasdaq
- Market Cap
- BROG 112.9M
- ATOS 96.8M
- IPO Year
- BROG N/A
- ATOS 2012
- Fundamental
- Price
- BROG $1.27
- ATOS $0.67
- Analyst Decision
- BROG
- ATOS Strong Buy
- Analyst Count
- BROG 0
- ATOS 3
- Target Price
- BROG N/A
- ATOS $7.00
- AVG Volume (30 Days)
- BROG 22.8K
- ATOS 516.6K
- Earning Date
- BROG 04-08-2025
- ATOS 03-25-2025
- Dividend Yield
- BROG N/A
- ATOS N/A
- EPS Growth
- BROG N/A
- ATOS N/A
- EPS
- BROG N/A
- ATOS N/A
- Revenue
- BROG $73,020,415.00
- ATOS N/A
- Revenue This Year
- BROG N/A
- ATOS N/A
- Revenue Next Year
- BROG N/A
- ATOS N/A
- P/E Ratio
- BROG N/A
- ATOS N/A
- Revenue Growth
- BROG N/A
- ATOS N/A
- 52 Week Low
- BROG $0.80
- ATOS $0.66
- 52 Week High
- BROG $6.66
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- BROG 52.25
- ATOS 34.82
- Support Level
- BROG $1.15
- ATOS $0.66
- Resistance Level
- BROG $1.29
- ATOS $0.77
- Average True Range (ATR)
- BROG 0.10
- ATOS 0.04
- MACD
- BROG 0.01
- ATOS 0.00
- Stochastic Oscillator
- BROG 57.50
- ATOS 11.73
About BROG Brooge Energy Limited
Brooge Energy Ltd is an Oil Refinery & Storage Company in the United Arab Emirates. The company generates revenue from the leasing of storage capacity of tanks and other ancillary services.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.